Thrombin - Angiotech Pharmaceuticals

Drug Profile

Thrombin - Angiotech Pharmaceuticals

Alternative Names: Hemaseel Thrombin; Human thrombin - Haemacure; Thrombin hemostat

Latest Information Update: 19 Jul 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Haemacure Corporation
  • Developer Angiotech Pharmaceuticals
  • Class Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins; Serine endopeptidases
  • Mechanism of Action Thrombin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Haemorrhage

Most Recent Events

  • 29 Mar 2012 Suspended - Preclinical for Haemorrhage in Canada (Topical)
  • 07 Apr 2010 Angiotech Pharmaceuticals acquires certain assets of Haemacure Corporation, including its thrombin product
  • 19 Aug 2009 Preclinical development is ongoing in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top